Financings in Brief: Possis Medical
This article was originally published in The Gray Sheet
Possis Medical: Nets about $23.6 mil. from a public offering of 1.9 mil. shares of common at $14.50 per share including 160,000 shares offered by selling shareholders. Plans for the offering were announced during the summer ("The Gray Sheet" Sept. 11, p. 13)...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.